Crossmark

Characteristics and clinical courses of patients with atypical haemolytic uraemic syndrome on dialysis withdrawal after eculizumab treatment: sub-analysis of post-marketing surveillance in Japan

Crossref DOI link: https://doi.org/10.1007/s40620-025-02433-z

Published Online: 2025-10-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ito, Shuichi https://orcid.org/0000-0002-5242-8987
Matsumoto, Masanori

Shimono, Akihiko

Teranishi, Hirofumi

Maruyama, Shoichi
Funding

Funding for this research was provided by:

Alexion Pharma GK
License Information

Text and Data Mining valid from 2025-10-28

Version of Record valid from 2025-10-28
More Information

Article History

Received: 20 February 2025

Accepted: 4 September 2025

First Online: 28 October 2025

Declarations

:

: SI, MM, and SM received consulting fees, honoraria for lectures and participation on advisory board from Alexion Pharma GK. AS and HT are employees of Alexion Pharma GK and shareholders of AstraZeneca.

: Requirements of ethical approval were waived because of the nature of the surveillance.

: No animals were involved in this research so a statement on their welfare does not apply.

: Requirements of obtaining informed consent from individual patients were waived because of the nature of the surveillance.

Document is current

Any future updates will be listed below